Skip to main content
. Author manuscript; available in PMC: 2014 Feb 26.
Published in final edited form as: J Rheumatol. 2013 Apr 1;40(5):617–623. doi: 10.3899/jrheum.121171

Table 2.

Timing of use of anti-tumor necrosis factor (anti-TNF) medication perioperatively.

Anti-TNF Stop Time, weeks ± SD, n = 71 Restart Times, weeks ± SD, n = 23
Etanercept (n = 59)
Standard dosing: weekly
(t1/2= 3–5.5 days)		 2.4 ± 2.4 (n = 39)
range 1–14		 2.1 ± 1.1 (n = 15)
range 1–4
Golimumab (n = 2)
Standard dosing: weekly
(t1/2= 7–20 days)		 8 (n = 1)
range NA		 1.5 (n = 1)
range NA
Adalimumab (n = 25)
Standard dosing: every 2 weeks
(t1/2 = 10–20 days)		 5 ± 5.6 (n = 20)
range 1–24		 2 ± 1 (n = 3)
range 1–3
Infliximab (n = 18)
Standard dosing: every 4–8 weeks
(t1/2 = 7–12 days)		 4.8 ± 2.2 (n = 11)
range 2–9		 4.4 ± 1.8 (n = 4)
Range 2–4

t1/2 half-life. NA: not available.